Table 5. Antimicrobial resistance profiles of Staphylococcus aureus from healthy people, and methicillin-resistance Staphylococcus aureus (MRSA) isolates from clinical cases.
| Antimicrobial resistance profile | Antimicrobial subclasses | Samples | Type | Samples |
|---|---|---|---|---|
| -----------No.---------- | --No.-- | ---------------No.--------------- | ||
| ERY-PEN-TET-CIP-KAN | 5 | 5 | Clinical MRSA a | 2 |
| Healthy human | 3 | |||
| ERY-PEN-CIP-KAN-QUI | 5 | 1 | Clinical MRSA a | 1 |
| ERY-PEN-CIP-KAN-DAP | 5 | 5 | Clinical MRSA a | 5 |
| ERY-PEN-CIP-KAN | 4 | 29 | Clinical MRSA a | 25 |
| Clinical MRSA b | 2 | |||
| Healthy human | 2 | |||
| ERY-PEN-CIP-DAP | 4 | 1 | Clinical MRSA a | 1 |
| ERY-PEN-TET | 3 | 2 | Healthy human | 2 |
| ERY-PEN-KAN | 3 | 3 | Clinical MRSA a | 2 |
| Healthy human | 1 | |||
| ERY-CIP-KAN | 3 | 1 | Clinical MRSA a | 1 |
| PEN-TET-CIP | 3 | 1 | Clinical MRSA a | 1 |
| PEN-CIP-KAN | 3 | 2 | Clinical MRSA a | 1 |
| Healthy human | 1 | |||
| ERY-PEN-CIP | 3 | 55 | Clinical MRSA a | 51 |
| Healthy human | 4 | |||
| ERY-PEN | 2 | 9 | Clinical MRSA a | 36 |
| Healthy human | 6 | |||
| PEN-CIP | 2 | 8 | Clinical MRSA a | 3 |
| Healthy human | 5 | |||
| ERY-CIP | 2 | 1 | Clinical MRSA a | 1 |
| ERY | 1 | 2 | Healthy human | 2 |
| PEN | 1 | 22 | Clinical MRSA a | 6 |
| Healthy human | 16 | |||
| CIP | 1 | 2 | Clinical MRSA a | 2 |
Ciprofloxacin (CIP); Daptomycin (DAP); erythromycin (ERY); kanamycin (KAN); quinupristin/dalfopristin (QUI); penicillin (PEN); and tetracycline (TET).
a mecA positive.
b mecA and mecC negative.
Resistance according to CLSI (2012) criteria [34].